CA2079802A1 - Walk-through mutagenesis - Google Patents

Walk-through mutagenesis

Info

Publication number
CA2079802A1
CA2079802A1 CA002079802A CA2079802A CA2079802A1 CA 2079802 A1 CA2079802 A1 CA 2079802A1 CA 002079802 A CA002079802 A CA 002079802A CA 2079802 A CA2079802 A CA 2079802A CA 2079802 A1 CA2079802 A1 CA 2079802A1
Authority
CA
Canada
Prior art keywords
antibodies
libraries
amino acids
mutagenesis
function
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002079802A
Other languages
French (fr)
Other versions
CA2079802C (en
Inventor
Roberto Crea
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2079802A1 publication Critical patent/CA2079802A1/en
Application granted granted Critical
Publication of CA2079802C publication Critical patent/CA2079802C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0002—Antibodies with enzymatic activity, e.g. abzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/503—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses
    • C12N9/506—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses derived from RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/034—Fusion polypeptide containing a localisation/targetting motif containing a motif for targeting to the periplasmic space of Gram negative bacteria as a soluble protein, i.e. signal sequence should be cleaved

Abstract

A method of mutagenesis by which a predetermined amino acid is introduced into each and every position of a selected set of positions in a preselected region (or several different regions) of a protein to produce library of mutants. The method is based on the premise that certain amino acids play crucial role in the structure and function of proteins. Libraries can be generated which contain a high proportion of the desired mutants and are of reasonable size for screening. These libraries can be used to study the role of specific amino acids in protein structure and function and to develop new or improved proteins and polypep-tides such as enzymes, antibodies, single chain antibodies and catalytic antibodies.
CA002079802A 1990-04-05 1991-04-05 Walk-through mutagenesis Expired - Lifetime CA2079802C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50531490A 1990-04-05 1990-04-05
US505,314 1990-04-05
PCT/US1991/002362 WO1991015581A1 (en) 1990-04-05 1991-04-05 Walk-through mutagenesis

Publications (2)

Publication Number Publication Date
CA2079802A1 true CA2079802A1 (en) 1991-10-06
CA2079802C CA2079802C (en) 2001-09-18

Family

ID=24009833

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002079802A Expired - Lifetime CA2079802C (en) 1990-04-05 1991-04-05 Walk-through mutagenesis

Country Status (8)

Country Link
US (3) US5798208A (en)
EP (1) EP0527809B1 (en)
JP (2) JP4251406B2 (en)
AT (1) ATE126535T1 (en)
CA (1) CA2079802C (en)
DE (1) DE69112207T2 (en)
ES (1) ES2078518T3 (en)
WO (1) WO1991015581A1 (en)

Families Citing this family (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030194807A1 (en) * 1992-11-02 2003-10-16 Roberto Crea Walk-through mutagenesis
EP0695353B1 (en) * 1993-04-09 2001-12-12 Catalytic Antibodies, Inc. Selecting genes encoding catalytic antibodies
US6309883B1 (en) 1994-02-17 2001-10-30 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US6117679A (en) 1994-02-17 2000-09-12 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US6995017B1 (en) 1994-02-17 2006-02-07 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US20060257890A1 (en) 1996-05-20 2006-11-16 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US6335160B1 (en) 1995-02-17 2002-01-01 Maxygen, Inc. Methods and compositions for polypeptide engineering
US6165793A (en) 1996-03-25 2000-12-26 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US5605793A (en) * 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US5683987A (en) * 1994-07-12 1997-11-04 The Board Of Regents Of The University Of Nebraska Therapeutic oligonucleotides targeting the human MDR1 and MRP genes
US6063562A (en) * 1994-09-16 2000-05-16 Sepracor, Inc. In vitro method for predicting the evolutionary response of HIV protease to a drug targeted thereagainst
US5602021A (en) * 1994-12-29 1997-02-11 Catalytic Antibodies, Inc. Method for generating proteolytic enzymes specific against a selected peptide sequence
US6238884B1 (en) 1995-12-07 2001-05-29 Diversa Corporation End selection in directed evolution
US6358709B1 (en) 1995-12-07 2002-03-19 Diversa Corporation End selection in directed evolution
US6537776B1 (en) * 1999-06-14 2003-03-25 Diversa Corporation Synthetic ligation reassembly in directed evolution
US5830696A (en) 1996-12-05 1998-11-03 Diversa Corporation Directed evolution of thermophilic enzymes
US20030219752A1 (en) * 1995-12-07 2003-11-27 Diversa Corporation Novel antigen binding molecules for therapeutic, diagnostic, prophylactic, enzymatic, industrial, and agricultural applications, and methods for generating and screening thereof
US6740506B2 (en) 1995-12-07 2004-05-25 Diversa Corporation End selection in directed evolution
US6713279B1 (en) 1995-12-07 2004-03-30 Diversa Corporation Non-stochastic generation of genetic vaccines and enzymes
US6939689B2 (en) 1995-12-07 2005-09-06 Diversa Corporation Exonuclease-mediated nucleic acid reassembly in directed evolution
AU5760698A (en) * 1996-12-20 1998-07-17 Unilever Plc Enzymatic bleach composition
US6153410A (en) * 1997-03-25 2000-11-28 California Institute Of Technology Recombination of polynucleotide sequences using random or defined primers
DE19731990A1 (en) * 1997-07-25 1999-01-28 Studiengesellschaft Kohle Mbh Process for the production and identification of new hydrolases with improved properties
US6670127B2 (en) * 1997-09-16 2003-12-30 Egea Biosciences, Inc. Method for assembly of a polynucleotide encoding a target polypeptide
CA2319114A1 (en) * 1998-01-30 1999-08-05 Donald L. Heefner Gene regulator fusion proteins and methods of using the same for determining resistance of a protein to a drug targeted thereagainst
US7153655B2 (en) * 1998-06-16 2006-12-26 Alligator Bioscience Ab Method for in vitro molecular evolution of protein function involving the use of exonuclease enzyme and two populations of parent polynucleotide sequence
US20090130718A1 (en) * 1999-02-04 2009-05-21 Diversa Corporation Gene site saturation mutagenesis
MXPA00009723A (en) * 1999-02-04 2003-09-22 Diversa Corp Non-stochastic generation of genetic vaccines and enzymes.
JP3399518B2 (en) * 1999-03-03 2003-04-21 インターナショナル・ビジネス・マシーンズ・コーポレーション Semiconductor structure and method of manufacturing the same
EP1161529A2 (en) * 1999-03-09 2001-12-12 Diversa Corporation End selection in directed evolution
US6251604B1 (en) 1999-08-13 2001-06-26 Genopsys, Inc. Random mutagenesis and amplification of nucleic acid
US7115712B1 (en) 1999-12-02 2006-10-03 Maxygen, Inc. Cytokine polypeptides
AU2001241939A1 (en) * 2000-02-28 2001-09-12 Maxygen, Inc. Single-stranded nucleic acid template-mediated recombination and nucleic acid fragment isolation
EP1276861A2 (en) * 2000-03-24 2003-01-22 Maxygen, Inc. Methods for modulating cellular and organismal phenotypes
DK2199393T3 (en) * 2000-04-17 2012-11-26 Dyax Corp New methods for building libraries of genetic packages that collectively show the members of a diverse family of peptides, polypeptides or proteins
US8288322B2 (en) 2000-04-17 2012-10-16 Dyax Corp. Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries
CA2411139A1 (en) * 2000-06-08 2001-12-13 James T. Willerson Inhibitors of c-reactive protein induced inflammation
FR2813314B1 (en) * 2000-08-25 2004-05-07 Biomethodes MASSIVE DIRECTED MUTAGENESIS PROCESS
WO2005012515A2 (en) 2003-04-29 2005-02-10 Pioneer Hi-Bred International, Inc. Novel glyphosate-n-acetyltransferase (gat) genes
US6958213B2 (en) 2000-12-12 2005-10-25 Alligator Bioscience Ab Method for in vitro molecular evolution of protein function
PT2316940E (en) 2000-12-18 2013-10-16 Dyax Corp Focused libraries of genetic packages
US20020086292A1 (en) 2000-12-22 2002-07-04 Shigeaki Harayama Synthesis of hybrid polynucleotide molecules using single-stranded polynucleotide molecules
WO2002092780A2 (en) * 2001-05-17 2002-11-21 Diversa Corporation Novel antigen binding molecules for therapeutic, diagnostic, prophylactic, enzymatic, industrial, and agricultural applications, and methods for generating and screening thereof
SE0102327D0 (en) 2001-06-28 2001-06-28 Active Biotech Ab A novel engineered superantigen for human therapy
US7647184B2 (en) * 2001-08-27 2010-01-12 Hanall Pharmaceuticals, Co. Ltd High throughput directed evolution by rational mutagenesis
US20040096826A1 (en) * 2002-01-30 2004-05-20 Evans Glen A. Methods for creating recombination products between nucleotide sequences
US20030224404A1 (en) * 2002-02-25 2003-12-04 Manuel Vega High throughput directed evolution of nucleic acids by rational mutagenesis
US20030171543A1 (en) * 2002-03-05 2003-09-11 Bott Richard R. High throughput mutagenesis screening method
US20030199068A1 (en) * 2002-03-05 2003-10-23 Bott Richard R. High throughput mutagenesis screening method
WO2003089671A1 (en) * 2002-04-17 2003-10-30 Roberto Crea 'doping' in walk-through mutagenesis
DE60328674D1 (en) * 2002-04-17 2009-09-17 Bioren Inc UNIVERSAL BANKS FOR IMMUNOGLOBULINE
ES2285118T5 (en) * 2002-05-17 2012-09-21 Alligator Bioscience Ab A METHOD FOR IN VITRO MOLECULAR DEVELOPMENT OF A PROTEIC FUNCTION.
EP2275536A1 (en) 2002-08-06 2011-01-19 Verdia, Inc. AP1 amine oxidase variants
EP2269618A1 (en) 2002-08-12 2011-01-05 Jennerex Biotherapeutics ULC An oncolytic vaccinia virus for use in combination with a chemotherapy for treating cancer.
US20040067532A1 (en) * 2002-08-12 2004-04-08 Genetastix Corporation High throughput generation and affinity maturation of humanized antibody
US7785799B2 (en) * 2002-08-16 2010-08-31 The Board Of Regents Of The University Of Texas System Compositions and methods related to flavivirus envelope protein domain III antigens
US7611700B2 (en) * 2002-09-09 2009-11-03 Hanall Pharmaceuticals, Co., Ltd. Protease resistant modified interferon alpha polypeptides
US20050118154A1 (en) 2003-04-02 2005-06-02 Mien-Chie Hung Antitumor effect of mutant Bik
WO2005003345A2 (en) * 2003-06-27 2005-01-13 R. Crea & Co. Look-through mutagenesis
EP2325339A3 (en) 2003-09-09 2011-11-02 Integrigen, Inc. Methods and compositions for generation of germline human antibody genes
MX2007000103A (en) 2004-07-06 2007-05-11 Bioren Inc Universal antibody libraries.
WO2006023144A2 (en) 2004-07-06 2006-03-02 Bioren Inc. Look-through mutagenesis for developing altered polypeptides with enhanced properties
CA2573259A1 (en) * 2004-07-06 2006-02-09 Bioren Inc. High affinity anti-tnf-alpha antibodies and method
EP1877441A2 (en) * 2005-04-26 2008-01-16 Bioren, Inc. Method of producing human igg antibodies with enhanced effector functions
US20070026012A1 (en) 2005-08-01 2007-02-01 Cornell Research Foundation, Inc. Compositions and methods for monitoring and altering protein folding and solubility
KR20090004839A (en) * 2005-09-07 2009-01-12 제네렉스, 인코포레이티드 Systemic treatment of metastatic and/or systemically-disseminated cancers using gm-csf-expressing poxviruses
US8980246B2 (en) 2005-09-07 2015-03-17 Sillajen Biotherapeutics, Inc. Oncolytic vaccinia virus cancer therapy
CA2627075A1 (en) 2005-11-14 2007-05-18 Bioren, Inc. Antibody ultrahumanization by predicted mature cdr blasting and cohort library generation and screening
GB2432366B (en) * 2005-11-19 2007-11-21 Alligator Bioscience Ab A method for in vitro molecular evolution of protein function
AU2007249160B2 (en) 2006-05-15 2013-09-12 I2 Pharmaceuticals, Inc. Neutralizing antibodies to influenza viruses
US20080108513A1 (en) * 2006-06-01 2008-05-08 Northwestern University Cellular Arrays
WO2008020079A1 (en) 2006-08-18 2008-02-21 Ablynx N.V. Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling
EP2064229B1 (en) 2006-09-15 2015-08-12 Ottawa Hospital Research Institute Oncolytic rhabdovirus
MX2009004221A (en) 2006-10-20 2009-09-10 Univ Arizona State Modified cyanobacteria.
US20090118130A1 (en) * 2007-02-12 2009-05-07 Codexis, Inc. Structure-activity relationships
US20100106585A1 (en) * 2007-04-17 2010-04-29 American Express Travel Related Services Company, Inc. System and method for evaluating positive behavior and offering incentives based upon limited use identifier transactions
US8470966B2 (en) 2007-08-10 2013-06-25 Protelica, Inc. Universal fibronectin type III binding-domain libraries
US8680019B2 (en) * 2007-08-10 2014-03-25 Protelica, Inc. Universal fibronectin Type III binding-domain libraries
US20090176654A1 (en) * 2007-08-10 2009-07-09 Protelix, Inc. Universal fibronectin type III binding-domain libraries
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
BRPI0816785A2 (en) * 2007-09-14 2017-05-02 Adimab Inc rationally designed synthetic antibody libraries, and uses thereof
JP2011504740A (en) 2007-11-27 2011-02-17 アブリンクス エン．ヴェー． Amino acid sequence directed to heterodimeric cytokines and / or their receptors, and polypeptides containing the same
US9873957B2 (en) 2008-03-13 2018-01-23 Dyax Corp. Libraries of genetic packages comprising novel HC CDR3 designs
CA2722409C (en) 2008-04-24 2017-12-12 Dyax Corp. Libraries of genetic packages comprising novel hc cdr1, cdr2, and cdr3 and novel lc cdr1, cdr2, and cdr3 designs
ES2620285T3 (en) 2008-05-02 2017-06-28 Novartis Ag Binding molecules based on improved fibronectin and their uses
ES2752025T3 (en) 2008-07-25 2020-04-02 Wagner Richard W Protein screening methods
JP5230397B2 (en) * 2008-12-18 2013-07-10 独立行政法人科学技術振興機構 Method for determining antigen-binding site of anti-transmembrane protein antibody
US8987433B2 (en) 2009-03-27 2015-03-24 Sapphire Energy, Inc. Variant isoprenoid producing enzymes and uses thereof
JP5647222B2 (en) 2009-04-10 2014-12-24 アブリンクス エン．ヴェー． Improved amino acid sequence directed against IL-6R for the treatment of IL-6R related diseases and disorders and polypeptides comprising the same
WO2010115995A2 (en) 2009-04-10 2010-10-14 Ablynx Nv Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders
US8945567B2 (en) 2009-06-05 2015-02-03 Ablynx N.V. Monovalent, bivalent and trivalent anti human respiratory syncytial virus (HRSV) nanobody constructs for the prevention and/or treatment of respiratory tract infections
CN107303302A (en) 2009-09-14 2017-10-31 希拉金股份有限公司 Oncolytic vaccinia virus combines cancer therapy
AU2010291902A1 (en) * 2009-09-14 2012-04-05 Dyax Corp. Libraries of genetic packages comprising novel HC CDR3 designs
EP3434769B1 (en) 2009-10-30 2020-11-25 Novartis AG Universal fibronectin type iii bottom-side binding domain libraries
WO2011051327A2 (en) 2009-10-30 2011-05-05 Novartis Ag Small antibody-like single chain proteins
WO2011051466A1 (en) 2009-11-02 2011-05-05 Novartis Ag Anti-idiotypic fibronectin-based binding molecules and uses thereof
EP2507262A1 (en) 2009-11-30 2012-10-10 Ablynx N.V. Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
MX337062B (en) 2009-12-10 2016-02-11 Ottawa Hospital Res Inst Oncolytic rhabdovirus.
WO2011092233A1 (en) 2010-01-29 2011-08-04 Novartis Ag Yeast mating to produce high-affinity combinations of fibronectin-based binders
EP3741883B1 (en) 2010-07-16 2022-12-14 Adimab, LLC Antibody libraries
EP2598529A2 (en) 2010-07-30 2013-06-05 Novartis AG Fibronectin cradle molecules and libraries thereof
CA2805941A1 (en) 2010-08-13 2012-02-16 Pioneer Hi-Bred International, Inc. Methods and compositions for targeting sequences of interest to the chloroplast
KR101942237B1 (en) 2011-01-04 2019-01-25 신라젠(주) Generation of antibodies to tumor antigens and generation of tumor specific complement dependent cytotoxicity by administration of oncolytic vaccinia virus
EP2718427B1 (en) 2011-06-08 2017-01-11 Children's Hospital of Eastern Ontario Research Institute Inc. Compositions for glioblastoma treatment
WO2013041722A1 (en) 2011-09-23 2013-03-28 Ablynx Nv Prolonged inhibition of interleukin-6 mediated signaling
RU2019133467A (en) 2011-10-11 2020-07-06 МЕДИММЬЮН, ЭлЭлСи CD40L-SPECIFIC FRAME STRUCTURES ORIGINING FROM TN3, AND METHODS OF APPLICATION
MX2014010495A (en) 2012-03-02 2014-11-14 Ablynx Nv Pseudomonas aeruginosa pcrv binding single variable domain antibodies.
CA2872096A1 (en) 2012-05-04 2013-11-07 E. I. Du Pont De Nemours And Company Compositions and methods comprising sequences having meganuclease activity
WO2014087010A1 (en) 2012-12-07 2014-06-12 Ablynx N.V. IMPROVED POLYPEPTIDES DIRECTED AGAINST IgE
CA2901501C (en) 2013-02-21 2023-03-07 Children's Hospital Of Eastern Ontario Research Institute Inc. Vaccine composition
WO2014153242A1 (en) 2013-03-14 2014-09-25 Pioneer Hi-Bred International, Inc. Compositions having dicamba decarboxylase activity and methods of use
WO2014153234A1 (en) 2013-03-14 2014-09-25 Pioneer Hi-Bred International, Inc. Compositions having dicamba decarboxylase activity and methods of use
WO2016062766A1 (en) 2014-10-21 2016-04-28 Ablynx Nv Treatment of il-6r related diseases
EP3268389B1 (en) 2015-03-12 2020-09-30 Medimmune, LLC Method of purifying albumin-fusion proteins
JP6962819B2 (en) 2015-04-10 2021-11-05 アディマブ， エルエルシー Method for Purifying Heterodimer Multispecific Antibody from Parent Homodimer Antibody Species
WO2016187101A2 (en) 2015-05-21 2016-11-24 Full Spectrum Genetics, Inc. Method of improving characteristics of proteins
CA3028002A1 (en) 2016-06-27 2018-01-04 Juno Therapeutics, Inc. Method of identifying peptide epitopes, molecules that bind such epitopes and related uses
MA45491A (en) 2016-06-27 2019-05-01 Juno Therapeutics Inc CMH-E RESTRICTED EPITOPES, BINDING MOLECULES AND RELATED METHODS AND USES
WO2018237323A1 (en) 2017-06-23 2018-12-27 The Board Of Trustees Of The Leland Stanford Junior University Pde5a destabilizing domains
MA51154A (en) 2017-12-15 2020-10-21 Aleta Biotherapeutics Inc CD19 VARIANTS

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6130597A (en) * 1984-07-20 1986-02-12 Nippon Zeon Co Ltd Device for synthesizing polynucleotide
ZA893284B (en) * 1988-05-04 1990-03-28 Igen Inc Peptide analogs and their use as haptens to elicit catalytic antibodies
EP0417165B1 (en) * 1988-05-11 1994-01-26 Polygen Holding Corporation Polypeptide compounds having growth hormone releasing activity
IL91501A (en) * 1988-09-02 1998-03-10 Dyax Corp Generation of a variegated library of mutant potential binding proteins and screening of said library for proteins with a desired binding activity
US6780613B1 (en) * 1988-10-28 2004-08-24 Genentech, Inc. Growth hormone variants
US5096815A (en) * 1989-01-06 1992-03-17 Protein Engineering Corporation Generation and selection of novel dna-binding proteins and polypeptides
CA2009996A1 (en) * 1989-02-17 1990-08-17 Kathleen S. Cook Process for making genes encoding random polymers of amino acids
FI87028C (en) * 1989-12-22 1992-11-10 Nokia Mobile Phones Ltd METHOD OF RESULT OF EFFECTIVE PROCEDURE WITHOUT SPREADING OF EFFECTIVE EFFECTS AND COVERING OF METHODS
US5264563A (en) * 1990-08-24 1993-11-23 Ixsys Inc. Process for synthesizing oligonucleotides with random codons

Also Published As

Publication number Publication date
DE69112207T2 (en) 1996-03-28
JPH05506580A (en) 1993-09-30
JP4275922B2 (en) 2009-06-10
EP0527809B1 (en) 1995-08-16
ES2078518T3 (en) 1995-12-16
AU7741891A (en) 1991-10-30
JP2003135084A (en) 2003-05-13
JP4251406B2 (en) 2009-04-08
AU653152B2 (en) 1994-09-22
US6649340B1 (en) 2003-11-18
WO1991015581A1 (en) 1991-10-17
US5830650A (en) 1998-11-03
ATE126535T1 (en) 1995-09-15
CA2079802C (en) 2001-09-18
US5798208A (en) 1998-08-25
DE69112207D1 (en) 1995-09-21
EP0527809A1 (en) 1993-02-24

Similar Documents

Publication Publication Date Title
CA2079802A1 (en) Walk-through mutagenesis
WO2005003345A3 (en) Look-through mutagenesis
NO913186D0 (en) PROCEDURE FOR USING AND SYNTHESIS OF PEPTIDES.
CA2105300A1 (en) Process for the development of binding mini-proteins
MY102885A (en) Method for determining mimotopes.
NO973848L (en) Process for the preparation of hemoglobin-like protein
GB8901469D0 (en) Proteins and method for their production
ATE121752T1 (en) REMOVAL OF PROTEIN A FROM ANTIBODY PREPARATIONS.
FR2705341B1 (en) Process for the preparation of mixtures of N-acylated amino acids, mixtures of N-acylated alpha amino acids, and their uses
CA2184195A1 (en) Screening method for identifying ligands for target proteins
DE68903576D1 (en) SIGNAL PEPTIDES EFFECTIVE IN YEAST AND THEIR USE FOR THE SECRETORIC EXPRESSION OF HETEROLOGICAL PROTEINS.
NO944846L (en) Process for Preparation of Protein C
IL91475A0 (en) Production of gonadotropin superagonists by recombinant dna methods and said super agonists produced thereby
CA2057313A1 (en) Method of producing pathogen-resistant plants
CA2004387A1 (en) Cyclosporine binding protein and use in an assay for biologically-active cyclosporine
DE3880122D1 (en) METHOD FOR SOLUBILIZING INSOLUBLE PROTEIN.
KR900007299A (en) Method for manufacturing single cell protein by high concentration culture
Bitt et al. Amino acid analysis of culture media and autolyzates by the method of capillary gas chromatography.
DE8817263U1 (en) Enzyme immunoassay for the detection of anti-tetanus antibodies
WO1991014707A3 (en) Production of electrophoretically-uniform protein-colloidal gold complexes
NO901843D0 (en) PROCEDURE FOR THE PRODUCTION OF GONADOTROPIN AND TSH SUPERAGONISTS.
ATE92102T1 (en) GENE FRAGMENTS ENCODING THE VARIABLE REGION OF AN ANTI-HIV ANTIBODY, CHIMAERE ANTI-HIV ANTIBODIES EXPRESSED BY THEM, AND METHODS FOR THEIR PRODUCTION.

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry